Enzymatic DNA Synthesis Market Size 2021 to 2034, Reaching USD 2.86 Billion at a 26.7% CAGR
The global enzymatic DNA synthesis market size was valued at USD 0.34 billion in 2025 and is projected to reach USD 2.86 billion by 2034, expanding at a robust CAGR of 26.7% from 2026 to 2034. The expanding biotechnology sector is creating an increased demand for next-gen DNA manufacturing platforms. Furthermore, increased research funding for genomics and drug development is driving market growth.
Market Overview
Enzymatic DNA synthesis is a method to synthesize DNA by using enzymes as opposed to traditional chemical processes. This is done through the use of biological catalysts in which nucleotides are added in an orderly fashion. This technique enables the formation of custom DNA sequences for synthetic biology and genetic research, among other applications. North America accounted for the largest enzymatic DNA synthesis market share of 47.50% in 2025, driven by the presence of leading biotechnology and pharmaceutical companies. Meanwhile, Asia Pacific is projected to witness rapid growth at a 29.50% CAGR, fueled by government initiatives in synthetic biology and life sciences.
🌐𝐁𝐫𝐨𝐰𝐬𝐞 𝐅𝐮𝐥𝐥 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:
Key Market Growth Drivers
Expanding Biotechnology Sector Driving Adoption of Advanced DNA Synthesis Technologies: Demand for custom DNA is rising in biotech research. In synthetic biology, designed DNA is used to construct and test out biological systems. In drug development, DNA is also required to understand genes and test out possible medicines. Enzymatic DNA synthesis serves as an alternative to chemical synthesis of DNA, facilitating easier production while minimizing the use of hazardous chemicals.
Growing Research Funding in Genomics and Drug Development: Research funding supports the development of technologies used for enzymatic DNA synthesis. For instance, the U.S. National Institutes of Health recognized the new developments in enzymatic strategies for oligonucleotide and nucleic acid construct syntheses in March 2026, noting the importance of rapid and affordable genomic techniques.
Key Dynamics
Transition from Chemical to Enzymatic Processes: Traditional chemical synthesis employs phosphoramidite chemistry, which generates chemical waste using hazardous reagents and struggles with lengths beyond 300 bases. In contrast, enzymatic synthesis uses mild, aqueous conditions where an enzyme adds nucleotides one at a time, allowing enzymatic fragments to be assembled into clonal constructs up to 50 kb.
Integration of Benchtop Automation and AI: DNA synthesis is moving toward simpler equipment and greater automation. Benchtop DNA synthesizers allow scientists to synthesize their DNA nearer to the location of need. Additionally, AI and machine learning methods enable scientists to prepare the DNA synthesis process before production, predicting possible errors and defining favorable conditions for targeted sequences.
Market Challenges and Opportunities
High Development Costs and Limited Production Capacity: The development of DNA enzymatic synthesis requires significant investments to optimize processes for commercial requirements. Specific equipment and qualified personnel create expenses that are difficult for smaller firms to manage, while scaling up laboratory processes to large-scale operations presents fidelity and accuracy hurdles.
Growing Demand from Synthetic Biology and Biomanufacturing: Synthetic biology depends on customized DNA to create and experiment with novel biological systems and biomaterials.
New Uses in Medicine, Data Storage, and DNA Design: Gene therapy and advanced diagnostics require specific DNA sequences. Additionally, research into using DNA as a medium for data storage and the integration of artificial intelligence tools provide vast new opportunities for enzymatic methods.
🌐𝐁𝐫𝐨𝐰𝐬𝐞 𝐅𝐮𝐥𝐥 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:
Market Key Companies
The enzymatic DNA synthesis market includes key players developing innovative techniques for the production of customized DNA:
Ansa Biotechnologies, Inc.
Camena Bioscience Limited
Codexis, Inc.
DNA Script SAS
Elegen Corporation
Evonetix Ltd.
4basebio PLC
GenScript Biotech Corporation
Integrated DNA Technologies, Inc.
Kern Systems, Inc.
Moligo Technologies AB
Molecular Assemblies, Inc.
Telesis Bio, Inc.
Touchlight
Twist Bioscience Corporation
Market Segmentation
By Services: Oligonucleotide Synthesis (46.00% market share in 2025), Gene Synthesis, Vaccine Development, and Others.
By Technology: Polymerase-based Enzymatic Synthesis (44.25% share in 2025), TdT-based Enzymatic Synthesis (30.42% CAGR), Ligation-based Enzymatic Synthesis, and Other Enzymatic Synthesis Technologies.
By Application: Gene & Genome Engineering (18.50% share in 2025), Therapeutic & Vaccine Development, Protein & Antibody Engineering, Molecular Diagnostics, Genomics & Sequencing, Synthetic Biology, DNA Data Storage (39.58% CAGR), and Others.
By End Users: Pharmaceutical & Biotechnology Companies (50.50% market share in 2025), Diagnostics & Genomics Companies, CROs & CDMOs (30.20% CAGR), Academic & Research Institutions, and Others.
By Region: North America (47.50% market share in 2025), Europe (25.00% market share in 2025), Asia Pacific, Latin America, and Middle East & Africa.
Market Trends
Rise of Benchtop Platforms: Adoption of benchtop DNA printers like DNA Script's SYNTAX platform is enabling laboratories to perform on-site, automated oligonucleotide synthesis.
Long and Ultra-Long DNA Constructs: Advances in long-DNA synthesis, such as Integrated DNA Technologies' partnership with Ansa Biotechnologies, now provide clonal DNA constructs up to 50 kb.
Sustainable DNA Manufacturing: Companies are increasingly adopting cell-free enzymatic workflows to cut back on chemical reagents and reduce the environmental footprint of DNA manufacturing.
Future Outlook
Increased demand for custom DNA in synthetic biology and genomic studies will continue to benefit the enzymatic DNA synthesis market. Precision medicine and gene therapy are expected to unlock further applications for the technology. Advances in enzyme engineering will likely enhance sequence precision and allow for the generation of longer DNA constructs. Furthermore, automation and artificial intelligence will continue to streamline sequence generation on a commercial scale.
Comments